$84.87
-4.0%Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Negative working capital indicates short-term liabilities exceed short-term assetsโpotential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial stress indicators: Both liquidity and leverage metrics raise concerns. The company may face challenges meeting obligations and should focus on strengthening its balance sheet.
CL โข NYSE
| Colgate-Palmolive Company Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||||||||||||
CURRENT ASSETS | ||||||||||||||||||||
1.3B | 1.1B | 966M | 775M | 832M | 888M | 883M | 726M | 1.5B | 1.3B | 970M | 1.1B | 962M | 884M | 878M | 490M | 600M | 554.9M | 428.7M | 489.5M | |
0.0 | 160M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.3B | 1.3B | 966M | 775M | 832M | 888M | 883M | 726M | 1.5B | 1.3B | 970M | 1.1B | 962M | 884M | 878M | 490M | 600M | 555M | 428.7M | 489.5M | |
1.7B | 1.5B | 1.6B | 1.5B | 1.3B | 1.3B | 1.4B | 1.4B | 1.5B | 1.4B | 1.4B | 1.6B | 1.6B | 1.7B | 1.7B | 1.6B | 1.6B | 1.6B | 1.7B | 1.5B | |
1.7B | 1.5B | 1.6B | 1.5B | 1.3B | 1.3B | 1.4B | 1.4B | 1.5B | 1.4B | 1.4B | 1.6B | 1.6B | 1.7B | 1.7B | 1.6B | 1.6B | 1.6B | 1.7B | 1.5B | |
2B | 2B | 1.9B | 2.1B | 1.7B | 1.7B | 1.4B | 1.3B | 1.2B | 1.2B | 1.2B | 1.4B | 1.4B | 1.4B | 1.3B | 1.2B | 1.2B | 1.2B | 1.2B | 1B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -12.2M | 0.0 | 0.0 | |
714M | 553M | 793M | 760M | 576M | 513M | 456M | 417M | 403M | 441M | 807M | 840M | 799M | 639M | 522M | 408M | 375M | 366.1M | 338.1M | 279.9M | |
5.7B | 5.3B | 5.3B | 5.1B | 4.4B | 4.3B | 4.2B | 3.8B | 4.6B | 4.3B | 4.4B | 4.9B | 4.8B | 4.6B | 4.4B | 3.7B | 3.8B | 3.7B | 3.6B | 3.3B | |
NON-CURRENT ASSETS | ||||||||||||||||||||
4.7B | 4.4B | 4.6B | 4.3B | 3.7B | 3.7B | 3.8B | 3.9B | 4.1B | 3.8B | 3.8B | 4.1B | 4.1B | 3.8B | 3.7B | 3.7B | 3.5B | 3.1B | 3B | 2.7B | |
3.1B | 3.3B | 3.4B | 3.4B | 3.3B | 3.8B | 3.5B | 2.5B | 2.2B | 2.1B | 2.1B | 2.3B | 2.5B | 2.5B | 2.7B | 2.4B | 2.3B | 2.2B | 2.3B | 2.1B | |
1.5B | 1.8B | 1.9B | 1.9B | 2.5B | 2.9B | 2.7B | 1.6B | 1.3B | 1.3B | 1.3B | 1.4B | 1.5B | 1.5B | 1.3B | 831M | 821M | 833.5M | 844.8M | 831.1M | |
4.7B | 5B | 5.3B | 5.3B | 5.7B | 6.7B | 6.2B | 4.2B | 3.6B | 3.4B | 3.4B | 3.7B | 4B | 4B | 4B | 3.7B | 3.8B | 3.1B | 3.1B | 2.9B | |
0.0 | 81M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 195M | 214M | 135M | 193M | 291M | 177M | 152M | 188M | 301M | 67M | 76M | 77M | 92M | 115M | 108M | 82M | 81.9M | 264.1M | 309.9M | |
1.3B | 1B | 1B | 904M | 974M | 857M | 753M | 168M | 218M | 224M | 239M | 720M | 924M | 905M | 541M | 556M | 685M | 164M | 361.5M | 228M | |
10.6B | 10.7B | 11.1B | 10.6B | 10.6B | 11.6B | 10.9B | 8.4B | 8B | 7.8B | 7.6B | 8.6B | 9.1B | 8.8B | 8.3B | 7.4B | 7.3B | 6.3B | 6.5B | 5.8B | |
16.3B | 16B | 16.4B | 15.7B | 15B | 15.9B | 15B | 12.2B | 12.7B | 12.1B | 12B | 13.5B | 13.9B | 13.4B | 12.7B | 11.2B | 11.1B | 10B | 10.1B | 9.1B | |
LIABILITIES | ||||||||||||||||||||
CURRENT LIABILITIES | ||||||||||||||||||||
0.0 | 2.8B | 2.2B | 2B | 2B | 1.9B | 1.7B | 1.8B | 1.7B | 1.7B | 1.5B | 1.6B | 1.7B | 1.6B | 1.7B | 1.4B | 1.6B | 1.3B | 1.1B | 1B | |
0.0 | 1.8B | 1.7B | 1.6B | 1.5B | 1.4B | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 1.2B | 1.3B | 1.3B | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 1B | |
0.0 | 973M | 503M | 450M | 554M | 519M | 474M | 538M | 477M | 553M | 398M | 416M | 370M | 302M | 427M | 272M | 387M | 272M | 0.0 | 0.0 | |
0.0 | 2.1B | 2B | 1.8B | 1.7B | 1.9B | 1.6B | 1.5B | 1.6B | 1.5B | 1.6B | 1.7B | 1.9B | 1.7B | 1.6B | 1.7B | 1.7B | 1.4B | 1.8B | 1.5B | |
0.0 | 660M | 330M | 25M | 51M | 267M | 514M | 12M | 11M | 13M | 302M | 504M | 908M | 304M | 380M | 609M | 361M | 198M | 294M | 950.8M | |
0.0 | 107M | 95M | 108M | 137M | 137M | 145M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 565M | 503M | 450M | 554M | 519M | 474M | 538M | 477M | 553M | 398M | 416M | 261M | 302M | 392M | 272M | 387M | 272.4M | 262.7M | 161.5M | |
5.7B | 116M | 122M | 97M | 93M | 182M | 70M | 93M | 101M | 84M | 79M | 94M | 105M | 96M | 90M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
5.7B | 5.8B | 4.7B | 4B | 4.1B | 4.4B | 4B | 3.3B | 3.4B | 3.3B | 3.5B | 3.9B | 4.6B | 3.7B | 3.7B | 3.7B | 3.6B | 3B | 3.2B | 3.5B | |
NON-CURRENT LIABILITIES | ||||||||||||||||||||
8B | 7.3B | 8.2B | 8.7B | 7.2B | 7.3B | 7.3B | 6.4B | 6.6B | 6.5B | 6.2B | 5.6B | 4.7B | 4.9B | 4.4B | 2.8B | 2.8B | 3.6B | 3.2B | 2.7B | |
0.0 | 343M | 361M | 383M | 395M | 426M | 507M | 235M | 204M | 246M | 233M | 261M | 444M | 293M | 252M | 108M | 82M | 81.9M | 264.1M | 309.9M | |
2.2B | 1.7B | 1.7B | 1.4B | 2B | 2.2B | 2.1B | 2B | 2.3B | 2B | 2B | 2.2B | 1.7B | 2B | 1.8B | 1.7B | 1.4B | 1.5B | 1.1B | 1.2B | |
10.2B | 9.7B | 10.7B | 10.9B | 10B | 10.4B | 10.4B | 8.6B | 9B | 8.8B | 8.4B | 8.1B | 6.9B | 7.3B | 6.5B | 4.6B | 4.3B | 5B | 4.6B | 4.3B | |
0.0 | 563M | 515M | 505M | 588M | 613M | 636M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
16B | 15.5B | 15.4B | 14.9B | 14.1B | 14.8B | 14.5B | 12B | 12.4B | 12.1B | 12B | 12.1B | 11.3B | 11B | 10.2B | 8.4B | 7.9B | 8.1B | 7.7B | 7.7B | |
SHAREHOLDERS' EQUITY | ||||||||||||||||||||
0.0 | -27.4B | -26B | -25.1B | -24.1B | -23B | -22.1B | -21.2B | -20.2B | -19.1B | -18.1B | -16.9B | -15.6B | -14.4B | -12.8B | -11.3B | -10.5B | -9.7B | -8.9B | -8.1B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 169M | 181M | 197.5M | 222.7M | |
0.0 | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 733M | 733M | 733M | 733M | 732.9M | 732.9M | 732.9M | |
0.0 | 4.2B | 3.8B | 3.5B | 3.3B | 3B | 2.5B | 2.2B | 2B | 1.7B | 1.4B | 1.2B | 1B | 1.6B | 1.3B | 1.1B | 1.8B | 1.6B | 1.5B | 1.2B | |
0.0 | 26.1B | 25.3B | 24.6B | 24.4B | 23.7B | 22.5B | 21.6B | 20.5B | 19.9B | 18.9B | 18.8B | 18B | 17B | 15.6B | 14.3B | 13.2B | 11.8B | 10.6B | 9.6B | |
0.0 | -4.2B | -3.9B | -4.1B | -4.4B | -4.3B | -4.3B | -4.2B | -3.9B | -4.2B | -4B | -3.5B | -2.5B | -2.6B | -2.5B | -2.1B | -2.1B | -2.5B | -1.9B | -2.3B | |
54M | 0.0 | 0.0 | -1M | -1M | -1M | -2M | -3M | -5M | -7M | -12M | -20M | -33M | -41M | -60M | -99M | -133M | 600K | 0.0 | 0.0 | |
54M | 212M | 609M | 401M | 609M | 743M | 117M | -102M | -60M | -243M | -299M | 1.1B | 2.3B | 2.2B | 2.4B | 2.7B | 3.1B | 1.9B | 2.3B | 1.4B | |
365M | 544M | 957M | 806M | 971M | 1.1B | 558M | 197M | 243M | 17M | -44M | 1.4B | 2.5B | 2.4B | 2.5B | 2.8B | 3.3B | 1.9B | 2.4B | 1.4B | |
311M | 332M | 348M | 405M | 362M | 358M | 441M | 299M | 303M | 260M | 255M | 240M | 231M | 201M | 166M | 142M | 141M | 0.0 | 109.9M | 0.0 | |
SUMMARY | ||||||||||||||||||||
16.3B | 16B | 16.4B | 15.7B | 15B | 15.9B | 15B | 12.2B | 12.7B | 12.1B | 12B | 13.5B | 13.9B | 13.4B | 12.7B | 11.2B | 11.1B | 10B | 10.1B | 9.1B | |
0.0 | 241M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8B | 8.5B | 9.1B | 9.3B | 7.8B | 8.2B | 8.5B | 6.4B | 6.6B | 6.5B | 6.5B | 6.1B | 5.7B | 5.2B | 4.8B | 3.4B | 3.2B | 3.8B | 3.5B | 3.7B | |
6.7B | 7.4B | 8.1B | 8.5B | 7B | 7.3B | 7.6B | 5.6B | 5B | 5.2B | 5.6B | 5.1B | 4.7B | 4.3B | 3.9B | 2.9B | 2.6B | 3.2B | 3.1B | 3.2B | |
806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 | 806,133,625 |
CL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 13, 2026 | May 08, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 03, 2025 | 2025 |
Continue your CL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.